Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 509-516

  Lok, Anna S ^a   Pan, Calvin Q ^b   Han, Steven Huy B ^c   Trinh, Huy N ^d   Fessel, W Jeffrey ^e   Rodell, Timothy ^f   Massetto, Benedetta ^g   Lin, Lanjia ^g   Gaggar, Anuj ^g   Subramanian, G Mani ^g   McHutchison, John G ^g   Ferrari, Carlo ^h   Lee, Hannah ⁱ   Gordon, Stuart C ^j   Gane, Edward J ^k  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d San Jose Gastroenterology   (United States)

^e KAISER PERMANENTE   (United States)

^f GlobeImmune Inc   (United States)

^g GILEAD SCIENCES   (United States)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ TUFTS MEDICAL CENTER   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

GS 4774; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B virus; Nucleoside nucleotide analogue; Phase II

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; GS 4774; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; VIRUS DNA;

ABSCESS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CELLULAR IMMUNITY; CHRONIC HEPATITIS B; COLON DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDE ATTEMPT; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; CLINICAL TRIAL; HEPATITIS B VIRUS; MIDDLE AGED; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84991093310     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.016     Document Type: Article

References (29)

1. [1] Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
2. [2] Lavanchy, D., Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004), 97–107.
3. [3] Marcellin, P., Lau, G.K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004), 1206–1217.
4. [4] P. Marcellin, E.J. Heathcote, Buti, M., Gane, E., de Man, R.A., Krastev, Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008), 2442–2455.
5. [5] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
6. [6] Terrault, N.A., Bzowej, N.H., Chang, K.M., Hwang, J.P., Jonas, M.M., Murad, M.H., AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
7. [7] Hou, J., Schilling, R., Janssen, H.L., Hansen, B.E., Heijtink, R., Sablon, E., et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 79 (2007), 1055–1063.
8. [8] Janssen, H.L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U.S., Cakaloglu, Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005), 123–129.
9. [9] Perrillo, R.P., Lai, C.L., Liaw, Y.F., Dienstag, J.L., Schiff, E.R., Schalm, S.W., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002), 186–194.
10. [10] Kwon, J.H., Jang, J.W., Lee, S., Lee, J., Chung, K.W., Lee, Y.S., et al. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. J Viral Hepat 19 (2012), e41–e47.
11. [11] Tangkijvanich, P., Komolmit, P., Mahachai, V., Sa-nguanmoo, P., Theamboonlers, A., Poovorawan, Y., Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. Clin Virol 46 (2009), 117–123.
12. [12] Lee, M.H., Lee da, M., Kim, S.S., Cheong, J.Y., Cho, S.W., Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B. J Med Virol 83 (2011), 1178–1186.
13. [13] Takkenberg, R.B., Jansen, L., de Niet, A., Zaaijer, H.L., Weegink, C.J., Terpstra, V., et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antivir Ther 18 (2013), 895–904.
14. [14] Manesis, E.K., Hadziyannis, E.S., Angelopoulou, O.P., Hadziyannis, S.J., Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 12 (2007), 73–82.
15. [15] Bertoletti, A., Gehring, A.J., The immune response during hepatitis B virus infection. J Gen Virol 87 (2006), 1439–1449.
16. [16] Bertoletti, A., Ferrari, C., Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61 (2012), 1754–1764.
17. [17] Webster, G.J., Reignat, S., Maini, M.K., Whalley, S.A., Ogg, G.S., King, A., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32 (2000), 1117–1124.
18. [18] Vandepapeliere, P., Lau, G.K., Leroux-Roels, G., et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 12 (2007), 8585–8597.
19. [19] Hoa, P.T., Huy, N.T., Thu le, T., et al. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 53 (2009), 5134–5140.
20. [20] Xu, D.-Z., Zhao, K., Guo, L.-M., Chen, X.-Y., Wang, H.-F., Zhang, J.-M., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One, 3, 2008, e2565.
21. [21] Martin, P., Dubois, C., Jacquier, E., Dion, S., Mancini-Bourgine, M., Godon, O., et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 64 (2015), 1961–1971.
22. [22] Kosinska, A., Zhang, E., Johrden, L., Liu, J., Seiz, P., Zhang, X., et al. Combination of DNA prime – Adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog, 9, 2013, e1003391.
23. [23] Heathcote, J., McHutchison, J., Lee, S., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30 (1999), 531–536.
24. [24] Gaggar, A., Coeshott, C., Apelian, D., Rodell, T., Armstrong, B.R., Shen, G., et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 32 (2014), 4925–4931.
25. [25] King, T.H., Kemmler, C.B., Guo, Z., Mann, D., Lu, Y., Coeshott, C., et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One, 9, 2014, e101904.
26. [26] Stubbs, A.C., Martin, K.S., Coeshott, C., Skaates, S.V., Kuritzkes, D.R., Bellgrau, D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7 (2001), 625–629.
27. [27] Chan, H.L., Wong, G.L., Choi, P.C., Chan, A.W., Chim, A.M., Yiu, K.K., et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 16 (2009), 36–44.
28. [28] Moucari, R., Mackiewicz, V., Lada, O., Ripault, M.P., Castelnau, C., Martinot-Peignoux, M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49 (2009), 1151–1157.
29. [29] Sonneveld, M.J., Zoutendijk, R., Flink, H.J., Zwang, L., Hansen, B.E., Janssen, H.L., Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 56 (2013), 100–105.